Thioguanine Pregnancy and Breastfeeding Warnings

Brand names: Tabloid

Medically reviewed by Drugs.com. Last updated on Apr 11, 2025.

Thioguanine Pregnancy Warnings

Use is recommended only if clearly needed and the benefit outweighs the risk.

AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned.

Risk summary: Based on animal data, this drug may cause fetal harm; animal studies have revealed evidence of fetotoxicity at clinically relevant doses.

Comments:
-This drug can harm a developing fetus.
-Adequate methods of contraception should be encouraged.
-Patients of childbearing potential should be advised to avoid becoming pregnant.
-There have been cases where men who have received combinations of cytotoxic agents including this drug have fathered children with congenital abnormalities.

Animal studies have revealed evidence of embryotoxicity, teratogenicity, and mutagenicity. There are no controlled data in human pregnancy. It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans.

AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Thioguanine Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments:
- Because of the potential for tumorigenicity shown for this drug, breastfeeding during therapy should be avoided.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer